REPROCELL News (8)

Nov 25, 2015

REPROCELL acquires Biopta to expand its drug discovery services

The Japanese regenerative medicine company REPROCELL Inc. has announced the acquisition of the Scottish life sciences company, Biopta.

Nov 18, 2015

Biopta co-authors research in the European Respiratory Journal

The impact of fresh human tissue studies for translational work performed at Biopta has once again been demonstrated with this latest publication at the European Respiratory Society.

Nov 18, 2015

Publication of Paper on “3D culture model construction of mouse neurons” in Neuroscience Letters

Reinnervate (now REPROCELL Europe) has written a paper on the topic of “3D culture model construction of mouse neurons”, along with other contributors including Durham University (UK), that has recently been published in ‘Neuroscience Letters’.

Nov 16, 2015

A Joint Development with the National Cancer Center Information Regarding the Sale of “ReproHP Medium,” a Culture Fluid for Human Primary Liver Cells with High Levels of Functionality

“ReproHP Medium,” a highly functional culture fluid for human primary liver cells developed in conjunction with the National Cancer Center, is set to go on sale in December this year.

Nov 04, 2015

Notice of Passage of Examination for United States Patent Application Concerning Amplification Method of Hematopoietic Stem Cells

REPROCELL like to inform you that a patent application concerning an amplification method of hematopoietic stem cells which we applied for jointly with Nissan Chemical Industries, Ltd., has passed screening in the United States.

Oct 19, 2015

REPROCELL announces publication of a research report on “3D Skin Model Construction,” submitted to the International Scientific Journal “Molecular Cancer Therapeutics” by REPROCELL and others

Read more about REPROCELL CSO Professor Stefan Przyborski's latest publication on 3D Skin Model Construction published in Molecular Cancer Therapeutics

Oct 14, 2015

The REPROCELL Group announces publication of a paper on its state-of-the-art RNA Reprogramming technology in Human Gene Therapy, an international journal

Group affiliate Stemgent Inc. (US) is pleased to announce the publication of a paper on state-of-the-art iPS cell production technology, entitled “RNA Reprogramming,” that was written collaboratively with the Whitehead Institute (USA).

Sep 08, 2015

REPROCELL concludes license agreement with Keio University for the exclusive sale of myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells

REPROCELL is pleased to announce that our company has entered into an exclusive licensing agreement with Keio University regarding myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells.

Aug 26, 2015

Announcement: New High Performance Cryopreservation Solution – ReproCryo DMSO Free

Read more about how REPROCELL's new high-performance cryopreservation solution ReproCryo (DMSO free) is advancing the field of regenerative medicine.

Aug 14, 2015

Announcement of Award for Prototype Development of Large-Scale Production on Human-iPSC derived Cardiomyocytes

REPROCELL would like to announce that on August 3rd, 2015, one of our projects, “Prototype Development of a Large- Scale Production Mechanism of Highly Functional Cardiomyocytes Derived From Human iPS Cells” (hereafter, “the project”) was selected to receive a Subsidy for Collaborative Projects to Advance the Creation of an Innovative Manufacturing Industry (FY 2015-2016).

Jul 29, 2015

Diseased neurons derived from iPS cells of Alzheimer’s disease patients Initiation of sales of “ReproNeuro AD-patient”

REPROCELL is pleased to announce that on August 10th our company began sales of “ReproNeuro AD-patient,” diseased neurons made from iPS cells derived from Alzheimer’s disease patients.

Jul 21, 2015

Announcement: sales commencement of “ReproNeuro MQ Medium”, a cell culture kit which enables the creation of high-functioning nerve cells derived from human iPS cells

This is a notice that we will on August 3rd 2015 commence sales of “ReproNeuro MQ Medium”, a cell culture kit which enables the creation of high-functioning nerve cells derived from human iPS cells.

Jul 01, 2015

Announcement of Award for Prototype Development of a Liver Cell Kit

REPROCELL is pleased to announce that one of our projects, “Prototype Development of a Liver Cell Kit Derived From Functional Human Induced Pluripotent Stem (iPS) Cells for Applications in Drug Discovery” has been selected as a recipient of Grant for Manufacturing, Commerce, and Service Innovation additionally allocated for FY 2014-2015.

Jun 30, 2015

Stemgent, a REPROCELL Group Company Announces a New High Performance Self-replicative RNA Reprogramming Kit

Read REPROCELL Group company Stemgent inc.'s announcement of a New High Performance Self-replicative RNA Reprogramming Kit: Stemgent StemRNA™-SR

Jun 04, 2015

REPROCELL Concludes the License Agreement with Keio University for the Exclusive Sale of Disease (Hypertrophic Cardiomyopathy) Type Myocardial Cells Derived from iPS Cells

Read about REPROCELLS exclusive distribution and licensing agreement with Keio University regarding myocardial cells originating from disease type iPS Cells

Apr 20, 2015

Alvetex® 3D cell culture platform reaches new heights with project aboard the International Space Station (ISS).

Market leading 3D cell culture company Reinnervate Ltd, part of the ReproCELL group, today announced that a rocket carrying its Alvetex® Scaffold technology blasted into Space this week. Alvetex will be used in experiments on board the International Space Station (ISS).

Mar 05, 2015

New paper demonstrates formation of spontaneously active neuronal networks by stem cell derived neurons in 3D Alvetex Scaffold culture system

A recently published paper by Imogen Smith et al. demonstrates the use of the Alvetex platform to culture 3D differentiated human neural stem cells.

Feb 02, 2015

Corporate News